Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
DRUG

epigallocatechin-gallate (Sunphenon)

200 mg twice daily, after 3 months 400 mg twice daily

DRUG

placebo

2 placebo capsules twice daily, after 3 months 4 placebo capsules twice daily

Trial Locations (2)

10117

NeuroCure Clinical Research Center, Charite University, Berlin, Berlin

13125

Outpatient Clinic for Neuroimmunology at the ECRC, Charite University, Berlin, Berlin

All Listed Sponsors
lead

Charite University, Berlin, Germany

OTHER

NCT00525668 - Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study) | Biotech Hunter | Biotech Hunter